Synergistic effects of GHRH and GHRP on GH release in humans — VialBase Research

Summary

Clinical study demonstrating that combined administration of GHRH (growth hormone-releasing hormone, the class CJC-1295 belongs to) and GHRP (growth hormone-releasing peptide, the class ipamorelin belongs to) produces synergistic — not merely additive — GH release in humans. This provides the scientific rationale for the popular CJC-1295/Ipamorelin combination protocol.

Key Findings

• Combined GHRH + GHRP stimulation produces GH release that is synergistic (greater than the sum of individual effects)
• GHRH and GHRP act through different receptors and complementary mechanisms
• GHRH acts primarily at the pituitary via the GHRH receptor
• GHRP acts through the ghrelin/GHS receptor (GHS-R1a) at both pituitary and hypothalamus
• Combined stimulation amplifies pulse amplitude while maintaining pulsatility
• Synergy is consistent across different age groups tested

Methodology

Clinical study in 24 healthy adults. Participants received GHRH alone, GHRP alone, or combined GHRH+GHRP via IV bolus. GH measured via frequent blood sampling (deconvolution analysis). Individual and combined responses compared with assessment of synergy versus additivity.

Limitations

• Used IV bolus dosing — different from SC injection used in practice
• Generic GHRH and GHRP used — not specifically CJC-1295 and ipamorelin
• Acute single-dose study — does not address chronic combined use
• No body composition or functional outcomes
• Small sample size

Relevance to Content

The scientific foundation for the CJC-1295/Ipamorelin stack. This study answers “why combine them?” — synergy through complementary receptor mechanisms. Essential citation for any content discussing the CJC-1295/Ipamorelin combination. The synergy argument is a strong selling point for the combination versus either agent alone.

See Also

• Parent compound: CJC-1295
• Ipamorelin